MedTrace Logo

Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

NCT02521077 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-06-27

No results posted yet for this study

Summary

This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.

Conditions

Interventions

DRUG

Ascorbic Acid

500 g ascorbic acid dissolved in 500 ml sterile water.

OTHER

Normal Saline

Saline 0.9%

Sponsors & Collaborators

  • Midwestern Regional Medical Center

    lead OTHER

Principal Investigators

  • Dennis Citrin, MD, PhD · Midwestern Regional Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2019-03-31
Completion
2019-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521077 on ClinicalTrials.gov